Supervised exercise improved quality of life and fatigue in men on androgen deprivation

The edition in brief

STAMINA randomised 700 men on androgen deprivation therapy across 15 NHS trusts to 12 months of supervised aerobic and resistance exercise with dietary and behavioural support, or optimised usual care. Prostate cancer-specific quality of life improved by 4.5 FACT-P points and fatigue by 1.9 FACIT-F points. In the phase 2 PARADIGM trial, 172 induction-eligible adults with AML, mostly with adverse-risk disease, had longer event-free survival with azacitidine-venetoclax than with intensive induction (14.5 vs 6.2 months, HR 0.57), with fewer severe infections and bleeds. HARMONi found ivonescimab plus chemotherapy extended progression-free survival over chemotherapy alone after third-generation EGFR-TKI progression (6.8 vs 4.4 months, HR 0.52), but overall survival did not reach significance (HR 0.79, 0.62–1.01). STAR-TREC's 12-month analysis in early rectal cancer found long-course chemoradiotherapy preserved the rectum more often than short-course radiotherapy (TME-free survival 78.5% vs 60.6%). GETUG AFU 18 found 80 Gy rather than 70 Gy with long-term ADT improved 10-year progression-free survival in high-risk prostate cancer (83.6% vs 72.2%). Today's pearl: write an exercise prescription on the same day you start androgen deprivation.